Rhythm Historical Financial Ratios
| RYTM Stock | USD 56.12 0.64 1.15% |
Rhythm Pharmaceuticals is promptly reporting on over 106 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 2.97, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.4 will help investors to properly organize and evaluate Rhythm Pharmaceuticals financial condition quickly.
Rhythm |
About Rhythm Financial Ratios Analysis
Rhythm PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Rhythm Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Rhythm financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Rhythm Pharmaceuticals history.
Rhythm Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Rhythm Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Rhythm Pharmaceuticals sales, a figure that is much harder to manipulate than other Rhythm Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Net Profit Margin
The percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue.Most ratios from Rhythm Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Rhythm Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.At this time, Rhythm Pharmaceuticals' Tangible Book Value Per Share is very stable compared to the past year. As of the 22nd of December 2024, Shareholders Equity Per Share is likely to grow to 2.97, while Operating Cash Flow Per Share is likely to drop (2.48).
| 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.44 | 1.9 | 2.0 | Days Of Inventory On Hand | 499.16 | 338.4 | 241.38 |
Rhythm Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Rhythm Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rhythm Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 2.98 | 7.88 | 1.74 | 5.74 | 15.62 | 16.4 | |
| Book Value Per Share | 7.72 | 3.77 | 5.73 | 5.07 | 2.94 | 2.97 | |
| Free Cash Flow Yield | (0.15) | (0.0931) | (0.31) | (0.12) | (0.0514) | (0.0539) | |
| Operating Cash Flow Per Share | (3.37) | (2.76) | (2.94) | (3.33) | (2.36) | (2.48) | |
| Capex To Depreciation | 4.06 | 0.31 | 4.69 | 2.56 | 0.0267 | 0.0254 | |
| Pb Ratio | 2.98 | 7.88 | 1.74 | 5.74 | 15.62 | 16.4 | |
| Free Cash Flow Per Share | (3.46) | (2.77) | (3.05) | (3.41) | (2.36) | (2.48) | |
| Roic | (0.5) | (0.8) | (0.58) | (0.68) | (1.08) | (1.03) | |
| Net Income Per Share | (3.7) | (2.96) | (1.37) | (3.51) | (3.2) | (3.36) | |
| Payables Turnover | 0.0801 | 0.14 | 0.1 | 0.44 | 1.9 | 2.0 | |
| Cash Per Share | 8.03 | 3.92 | 5.94 | 6.39 | 4.78 | 3.45 | |
| Pocfratio | (6.81) | (10.76) | (3.39) | (8.75) | (19.47) | (20.45) | |
| Capex To Operating Cash Flow | (0.0276) | (0.001754) | (0.0372) | (0.0247) | (3.45E-4) | (3.62E-4) | |
| Pfcf Ratio | (6.63) | (10.74) | (3.27) | (8.54) | (19.47) | (20.44) | |
| Days Payables Outstanding | 4.6K | 2.6K | 3.5K | 820.86 | 191.68 | 182.1 | |
| Roe | (0.48) | (0.79) | (0.24) | (0.69) | (1.09) | (1.03) | |
| Ev To Operating Cash Flow | (6.33) | (9.95) | (3.0) | (8.03) | (19.04) | (19.99) | |
| Pe Ratio | (6.21) | (10.04) | (7.28) | (8.29) | (14.36) | (15.07) | |
| Return On Tangible Assets | (0.44) | (0.7) | (0.21) | (0.49) | (0.57) | (0.6) | |
| Ev To Free Cash Flow | (6.16) | (9.94) | (2.89) | (7.83) | (19.03) | (19.98) | |
| Earnings Yield | (0.16) | (0.0996) | (0.14) | (0.12) | (0.0697) | (0.0731) | |
| Net Debt To E B I T D A | 0.64 | 0.4 | 0.72 | 0.83 | 0.35 | 0.33 | |
| Current Ratio | 12.38 | 10.1 | 7.1 | 8.9 | 5.58 | 7.23 | |
| Tangible Book Value Per Share | 7.72 | 3.77 | 5.63 | 4.92 | 2.82 | 2.94 | |
| Graham Number | 25.33 | 15.86 | 13.29 | 20.02 | 14.56 | 10.02 | |
| Shareholders Equity Per Share | 7.72 | 3.77 | 5.73 | 5.07 | 2.94 | 2.97 | |
| Capex Per Share | 0.0929 | 0.00485 | 0.11 | 0.0821 | 8.15E-4 | 7.74E-4 | |
| Graham Net Net | 7.27 | 3.45 | 5.05 | 4.24 | 2.22 | 2.71 | |
| Enterprise Value Over E B I T D A | (5.36) | (8.94) | (6.4) | (7.98) | (15.39) | (16.16) | |
| Price Earnings Ratio | (6.21) | (10.04) | (7.28) | (8.29) | (14.36) | (15.07) | |
| Price Book Value Ratio | 2.98 | 7.88 | 1.74 | 5.74 | 15.62 | 16.4 | |
| Price Earnings To Growth Ratio | (0.11) | 0.5 | 0.14 | (0.0531) | 1.63 | 1.71 | |
| Days Of Payables Outstanding | 4.6K | 2.6K | 3.5K | 820.86 | 191.68 | 182.1 | |
| Price To Operating Cash Flows Ratio | (6.81) | (10.76) | (3.39) | (8.75) | (19.47) | (20.45) | |
| Price To Free Cash Flows Ratio | (6.63) | (10.74) | (3.27) | (8.54) | (19.47) | (20.44) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.